AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BridgeBio Pharma 2025 Q1 Earnings Misses Targets as Net Income Declines 369%
Generated by AI AgentAinvest Earnings Report Digest
Wednesday, Apr 30, 2025 8:29 am ET1min read
BridgeBio Pharma (BBIO) reported its fiscal 2025 Q1 earnings on April 29, 2025. The company's performance fell short of expectations, with a significant widening of net losses compared to the previous year. Despite this, BridgeBio's revenue guidance remains in line, focusing on the continued growth of Attruby and advancements in its pipeline. The company anticipates modest growth in operating expenses for the rest of the year, supported by expected milestones.
Revenue
BridgeBio Pharma's revenue for Q1 2025 totaled $116.63 million, marking a 44.8% drop from $211.12 million in Q1 2024. The revenue decline was primarily due to a decrease in license and services revenue, which fell to $79.89 million. Meanwhile, net product revenue, driven by Attruby's U.S. sales, contributed $36.74 million.
Earnings/Net Income
The company's earnings per share (EPS) reflected a deeper loss of $0.88, compared to a $0.20 loss in the same quarter last year. BridgeBio's net loss widened to $169.61 million, a 369.0% increase from the $36.16 million loss in Q1 2024. This EPS result signifies a challenging quarter for the company.
Post-Earnings Price Action Review
Following the earnings report, Pharma's stock displayed a mixed response. Short-term investors have a higher probability of gains if earnings reports include revenue figures, with a 3-day win rate of 38.1%, a 10-day rate of 61.9%, and a 30-day rate of 57.1%. For net income, the win rates are slightly better, with short-term investors enjoying a moderate chance of gains. However, EPS figures show lower win rates, suggesting that investors may not benefit as much from reports focusing solely on EPS. Overall, reports that include revenue and net income figures tend to present better prospects for positive returns.
CEO Commentary
Neil Kumar, CEO, highlighted the robust performance of Attruby, attributing its success to strong clinical outcomes and safety. He expressed optimism about the company's ongoing trials and emphasized the importance of Attruby's low dropout rates and efficient NDA submissions.
Guidance
BridgeBio anticipates maintaining modest growth in quarterly operating expenses for the remainder of 2025, driven by Attruby sales. The company expects Attruby to reach $4.3 billion in peak sales, capturing 30% of a $15 billion market, and aims to achieve further pipeline milestones, including Phase 3 program data readouts within the next year.
Additional News
Recently, BridgeBio announced the approval of BEYONTTRA® by the UK Medicines and Healthcare Products Regulatory Agency for treating ATTR-CM, marking a significant milestone in expanding its market presence. The company also appointed Thomas Trimarchi, Ph.D., as President and Chief Financial Officer, reflecting strategic leadership changes. Additionally, BridgeBio priced $500 million aggregate principal amount of convertible senior notes due 2031 to refinance its senior secured debt, underscoring its commitment to managing long-term financial strategies.
Revenue
BridgeBio Pharma's revenue for Q1 2025 totaled $116.63 million, marking a 44.8% drop from $211.12 million in Q1 2024. The revenue decline was primarily due to a decrease in license and services revenue, which fell to $79.89 million. Meanwhile, net product revenue, driven by Attruby's U.S. sales, contributed $36.74 million.
Earnings/Net Income
The company's earnings per share (EPS) reflected a deeper loss of $0.88, compared to a $0.20 loss in the same quarter last year. BridgeBio's net loss widened to $169.61 million, a 369.0% increase from the $36.16 million loss in Q1 2024. This EPS result signifies a challenging quarter for the company.
Post-Earnings Price Action Review
Following the earnings report, Pharma's stock displayed a mixed response. Short-term investors have a higher probability of gains if earnings reports include revenue figures, with a 3-day win rate of 38.1%, a 10-day rate of 61.9%, and a 30-day rate of 57.1%. For net income, the win rates are slightly better, with short-term investors enjoying a moderate chance of gains. However, EPS figures show lower win rates, suggesting that investors may not benefit as much from reports focusing solely on EPS. Overall, reports that include revenue and net income figures tend to present better prospects for positive returns.
CEO Commentary
Neil Kumar, CEO, highlighted the robust performance of Attruby, attributing its success to strong clinical outcomes and safety. He expressed optimism about the company's ongoing trials and emphasized the importance of Attruby's low dropout rates and efficient NDA submissions.
Guidance
BridgeBio anticipates maintaining modest growth in quarterly operating expenses for the remainder of 2025, driven by Attruby sales. The company expects Attruby to reach $4.3 billion in peak sales, capturing 30% of a $15 billion market, and aims to achieve further pipeline milestones, including Phase 3 program data readouts within the next year.
Additional News
Recently, BridgeBio announced the approval of BEYONTTRA® by the UK Medicines and Healthcare Products Regulatory Agency for treating ATTR-CM, marking a significant milestone in expanding its market presence. The company also appointed Thomas Trimarchi, Ph.D., as President and Chief Financial Officer, reflecting strategic leadership changes. Additionally, BridgeBio priced $500 million aggregate principal amount of convertible senior notes due 2031 to refinance its senior secured debt, underscoring its commitment to managing long-term financial strategies.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet